Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results

Szabo, Timea Magdolna; Frigy, Attila; Nagy, Eniko Nemes

doi:10.3390/ijms222313053

Cited by 15 publications

(22 citation statements)

References 134 publications

(156 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in line with the given role of both the pro-inflammatory and anti-inflammatory mediators involved in modulation of heart failure. 21 Altogether, these results show, for the first time, that macrophages play a relevant role in the modulatory effects of Fen on the pro-inflammatory response and fibrosis, and in the improvement of ventricular function. Given the functional characteristics and the plasticity in their phenotype, monocytes/macrophages could be regarded as potential pharmacological targets for the treatment of various pathologies.…”

mentioning

confidence: 99%

Macrophages Mediate Healing Properties of Fenofibrate in Experimental Chagasic Cardiomyopathy

et al. 2023

View full text Add to dashboard Cite

Chronic cardiomyopathy is one of the most relevant outcomes of Chagas disease associated with parasite persistence and exacerbated inflammatory response. Fenofibrate, a third generation fibric acid derivative and peroxisome proliferator-activated receptor-α ligand, is involved in the regulation of inflammatory response. However, the participation of macrophages in this scenario has not been elucidated. Here we show, for the first time, that macrophages play a fundamental role in the fenofibrate-mediated modulation of heart pro-inflammatory response and fibrosis caused by the infection with Trypanosoma cruzi. Furthermore, macrophages are required for fenofibrate to improve the loss of ventricular function and this restoration correlates with an anti-inflammatory microenvironment. Understanding the contributions of macrophages to the healing properties of fenofibrate reinforces its potential use as a therapeutic drug, with the aim of helping to solve a public health problem, such as chronic Chagas disease.

show abstract

mentioning

confidence: 99%

Macrophages Mediate Healing Properties of Fenofibrate in Experimental Chagasic Cardiomyopathy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…So, it might be a potential therapeutic target in these severe patients. But despite attractive pathophysiological hypotheses, inflammatory blocking or modulation (by anti-IL6, anti-TNF for example) and blood purification techniques (such as Cytosorb®) have yielded conflicting results ( 13 , 14 ). They should only be discussed in the most severe patients as a rescue strategy based, for example, on a high level of plasma IL-6 or on the need for high doses of vasopressors, as recently suggested.…”

Section: Discussionmentioning

confidence: 99%

Incidence, management, and prognosis of post-ischaemic ventricular septal defect: Insights from a 12-year tertiary centre experience

Grandsaigne

Bouisset

Porterie

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundAmong mechanical complications of acute myocardial infarction, ventricular septal defect (VSD) is uncommon but still serious. The evolution of emergency coronary revascularisation paradoxically decreased our knowledge of this disease, making it even rarer.AimTo describe ischaemic VSD incidence, management, and associated in-hospital and 1-year outcomes over a 12-years period.MethodsA retrospective single-centre register of patients managed for ischaemic VSD between January 2009 and December 2020.ResultsNinety-seven patients were included representing 8 patients/ years and an incidence of 0.44% of ACS managed. The majority of the patients were 73-years-old males (n = 54, 56%) with STEMI presentation (n = 75, 79%) and already presented with Q necrosis on ECG (n = 70, 74%). Forty-nine (51%) patients underwent PCI, 60 (62%) inotrope/vasopressors infusion, and 70 (72%) acute mechanical circulatory support (IABP 62%, ECMO 13%, and Impella® 3%). VSD surgical repair was performed for 44 patients (45%) and 1 patient was transplanted. In-hospital mortality was 71%, and 86% at 1 year, without significant improvement over the decade. Surgery appears to be a protective factor [0.51 (0.28–0.94) p = 0.003], whereas age [1.06 (1.03–1.09), p < 0.001] and lactate [1.16 (1.09–1.23), p < 0.001] were linked to higher 1-year mortality. None of the patients that were managed medically survived 1 year.ConclusionPost-ischaemic VSD is a rare but serious complication still associated with high mortality. Corrective surgery is associated with better survival, however, timing, patient selection, and a place for mechanical circulatory support need to be defined.

show abstract

“…Regardless of whether the inflammation is the cause or the consequence of heart failure, it remains an important factor and a potential therapeutic target [ 71 ]. Although, several studies have been conducted in order to investigate the role of anti-inflammatory therapies, the results have hitherto been poor or controversial [ 72 ].…”

Section: Inflammationmentioning

confidence: 99%

Inflammation and Heart Failure: Searching for the Enemy—Reaching the Entelechy

Paraskevaidis

Farmakis

Papingiotis

et al. 2023

JCDD

View full text Add to dashboard Cite

The pivotal role of inflammation in the pathophysiology of heart-failure (HF) development and progression has long been recognized. High blood levels of pro-inflammatory and inflammatory markers are present and associated with adverse outcomes in patients with HF. In addition, there seems to be an interrelation between inflammation and neurohormonal activation, the cornerstone of HF pathophysiology and management. However, clinical trials involving anti-inflammatory agents have shown inconclusive or even contradictory results in improving HF outcomes. In the present review, we try to shed some light on the reciprocal relationship between inflammation and HF in an attempt to identify the central regulating factors, such as inflammatory cells and soluble mediators and the related inflammatory pathways as potential therapeutic targets.

show abstract

Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results

Cited by 15 publications

References 134 publications

Macrophages Mediate Healing Properties of Fenofibrate in Experimental Chagasic Cardiomyopathy

Macrophages Mediate Healing Properties of Fenofibrate in Experimental Chagasic Cardiomyopathy

Incidence, management, and prognosis of post-ischaemic ventricular septal defect: Insights from a 12-year tertiary centre experience

Inflammation and Heart Failure: Searching for the Enemy—Reaching the Entelechy

Contact Info

Product

Resources

About